Close Menu
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Prateek Group Brings The New Era of Luxury Real Estate

November 20, 2026

Top Bathroom Tile Brands in India: Wall, Floor and Anti-Skid Options Compared

November 20, 2026

COLORFUL India Strengthens After-Sales Support Through Association with Kaizen Infoserve

November 20, 2026
Facebook X (Twitter) Instagram
Trending
  • Prateek Group Brings The New Era of Luxury Real Estate
  • Top Bathroom Tile Brands in India: Wall, Floor and Anti-Skid Options Compared
  • COLORFUL India Strengthens After-Sales Support Through Association with Kaizen Infoserve
  • ORGATEC India 2026 Outlines a Roadmap for Growth Amid a 15% Rise in Commercial Real Estate Investments
  • From Needle and Thread to Virar’s Spotlight: DhaagaDhari’s Handmade Brand Wins Hearts at Virar Flea Market
  • Medvyn Builds a National Platform for India’s Doctors, Hospitals and Healthcare Talent, Led by Founder Hardik Gajjar
  • Meeta Kotadia brings international recognition to India, winning the 2nd Runner-Up title along with two prestigious special awards at the global beauty pageant.
  • The CHRO’s Real Job as per Tutul Consulting Goes Beyond Keeping People Happy and More Toward Shaping Enterprise Mindset
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World
The Startup StoryThe Startup Story
Home»Business»Optimus Pharma granted permission for Restricted Use under Emergency Situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR
Business

Optimus Pharma granted permission for Restricted Use under Emergency Situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR

By December 28, 2021No Comments
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Hyderabad (Telangana) [India], December 28: Hyderabad, Optimus Pharma announced launching of their front line COVID-19 medication Molnupiravir in the Indian market, as they have received permission the restricted emergency use for Covid-19 drug.  Optimus Pharma successfully completed the Phase 3 Clinical Trial on 1218 subjects across 29 geographical study sites all over India. “We want to cover maximum demographic diversity into our trial in order to obtain data across the different geographical regions of the country and conclusive evidence that Molnupiravir is able to bring about viral load reduction over 5 days of treatment duration,” said Chairman and Managing Director of Optimus Pharma, Dr D Srinivasa Reddy. Optimus Pharma has developed the API in the house at its R&D centre in Hyderabad. Optimus Pharma has revealed highly promising results of the drug in its ability to reduce viral load and bring out significant symptomatic improvement in patients’ health.

It is to be noted that in the Clinical Trial, Molnupiravir was administered to the subjects along with Standard of Care (SoC) medication as per the approved protocol by CDSCO. The trial was successful in establishing a clinical significant results of ‘Molnupiravir + SoC’ over ‘SoC’ arm.

  • Rate of hospitalization was less in Molnupiravir+SoC when compared to SoC group.
  • Greater clinical improvement observed in Molnupiravir + SoC arm compared to SOC alone by Day 5 and Day 10.
  • Proportion of subjects with RT-PCR negativity at Day 5 and Day 10 was statistically significant in Molnupiravir + SoC arm.
  • Higher viral load reduction was observed in Molnupiravir+ SoC arm
  • No serious safety concerns observed with Molnupiravir in overall study duration, no mortality was observed in the trial across both the arms

 Molnupiravir is administered as an 800 mg dose by orally consuming four capsules of 200mg twice a day. Upon oral administration, Molnupiravir, being a prodrug, is metabolized into its active form and converted into its triphosphate (TP) form. The TP form of Molnupiravir is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription, thereby significantly reducing viral replication.

Optimus Pharma is ready with a commercial quantity of the drug to cater to the unmet medical need of the nation. It is with heartfelt gratitude that we thank the Subject Expert Committee of the CDSCO and the DCGI for their valuable recommendations and guidance for the Clinical Trial, thereby making this project a huge success, said Dr D. Srinivas Reddy (MD Optimus) in his statement to the press. Optimus Pharma is committed to consistently integrating quality, affordability and reliability into their products and ensuring timely access to life-saving medication to whomsoever is in need.

Business
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

Related Posts

Prateek Group Brings The New Era of Luxury Real Estate

November 20, 2026

Top Bathroom Tile Brands in India: Wall, Floor and Anti-Skid Options Compared

November 20, 2026

COLORFUL India Strengthens After-Sales Support Through Association with Kaizen Infoserve

November 20, 2026

Comments are closed.

Top Posts

From Needle and Thread to Virar’s Spotlight: DhaagaDhari’s Handmade Brand Wins Hearts at Virar Flea Market

November 20, 2026

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020

Make your own inhouse library and learn

February 22, 2020
Don't Miss
Business

Prateek Group Brings The New Era of Luxury Real Estate

By Arjun SinghNovember 20, 2026

Fine living comes to Sector 150, with homes designed around privacy, nature and family life…

Top Bathroom Tile Brands in India: Wall, Floor and Anti-Skid Options Compared

November 20, 2026

COLORFUL India Strengthens After-Sales Support Through Association with Kaizen Infoserve

November 20, 2026

ORGATEC India 2026 Outlines a Roadmap for Growth Amid a 15% Rise in Commercial Real Estate Investments

November 20, 2026
Most Popular

From Needle and Thread to Virar’s Spotlight: DhaagaDhari’s Handmade Brand Wins Hearts at Virar Flea Market

November 20, 2026

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020
Categories
  • Business
  • Business News
  • Education
  • Entertainment
  • Finance
  • Health
  • Lifestyle
  • National
  • Press Release
  • Sports
  • Technology
  • Uncategorized
  • World
Our Picks

Prateek Group Brings The New Era of Luxury Real Estate

November 20, 2026

Top Bathroom Tile Brands in India: Wall, Floor and Anti-Skid Options Compared

November 20, 2026

COLORFUL India Strengthens After-Sales Support Through Association with Kaizen Infoserve

November 20, 2026

Type above and press Enter to search. Press Esc to cancel.